DK2552966T3 - Antistoffer mod csf-1r - Google Patents

Antistoffer mod csf-1r Download PDF

Info

Publication number
DK2552966T3
DK2552966T3 DK11713416.3T DK11713416T DK2552966T3 DK 2552966 T3 DK2552966 T3 DK 2552966T3 DK 11713416 T DK11713416 T DK 11713416T DK 2552966 T3 DK2552966 T3 DK 2552966T3
Authority
DK
Denmark
Prior art keywords
ser
leu
val
pro
gly
Prior art date
Application number
DK11713416.3T
Other languages
English (en)
Inventor
Jacqueline Francoise Doody
Yanxia Li
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Application granted granted Critical
Publication of DK2552966T3 publication Critical patent/DK2552966T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (16)

1. Antistof, der specifikt binder human CSF-1 R-variant (SEQ ID NO. 15), omfattende en tung kæde omfattende aminosyresekvensen SEQ ID NO:9 og en let kæde omfattende aminosyresekvensen SEQ ID NO:10.
2. Antistof, der specifikt binder human CSF-1 R (SEQ ID NO. 16), omfattende en tung kæde omfattende aminosyresekvensen SEQ ID NO:9 og en let kæde omfattende aminosyresekvensen SEQ ID NO:10.
3. Antistof ifølge krav 1 eller 2, omfattende to tunge kæder, som hver omfatter aminosyresekvensen SEQ ID NO:9, og to lette kæder, som hver omfatter aminosyresekvensen SEQ ID NO:10.
4. Farmaceutisk sammensætning omfattende antistoffet ifølge et hvilket som helst af kravene1-3 sammen med et farmaceutisk acceptabelt bærestof, fortyndingsmiddel eller hjælpestof.
5. Farmaceutisk sammensætning ifølge krav 4, yderligere omfattende et yderligere farmaceutisk middel.
6. Antistof ifølge et hvilket som helst af kravene 1-3 til anvendelse som et lægemiddel.
7. Antistof ifølge et hvilket som helst af kravene 1-3 til anvendelse ved behandling af cancer.
8. Antistof til anvendelse ifølge krav 7, hvor canceren er leukæmi, brystcancer, endometriecancer, prostatacancer, ovariecancer, kolorektal cancer, he-patocellulær cancer, renal cancer, myelomatose eller Hodgkins lymfom.
9. Antistof til anvendelse ifølge krav 8, hvor canceren er leukæmi, brystcancer, endometriecancer eller prostatacancer.
10. Antistof til anvendelse ifølge krav 9, hvor canceren er leukæmi, brystcancer eller prostatacancer.
11. Antistof til anvendelse ifølge krav 6-10, hvor antistoffet indgives før, under, i det væsentlige samtidig med, eller efter påbegyndelse af terapi med en anden anti-cancer-behandling.
12. Antistof til anvendelse ifølge krav 11, hvor anti-cancer-behandlingen er udvalgt fra gruppen bestående af et anti-angiogenese-middel, et kemoterapeutisk middel og et anti-neoplastisk middel.
13. Antistof til anvendelse ifølge krav 12, hvor det anti-neoplastiske middel er udvalgt fra gruppen bestående af docetaxel, paclitaxel, Herceptin® og doxorubicin.
14. Antistof til anvendelse ifølge et hvilket som helst af kravene 1-3 til anvendelse ved behandling af cancer hos en patient, omfattende måling af niveauet af CSF-1 i en prøve udtaget fra patienten, hvor prøven er udvalgt fra gruppen bestående af blod, serum, plasma, tumorceller og cirkulerende tumorceller, og indgivelse til patienten af antistoffet ifølge et hvilket som helst af kravene 1-3, hvis CSF-1-niveauerne er højere end CSF-1-niveauer fundet kos en kontrolpopulation.
15. Antistof ifølge et hvilket som helst af kravene 1-3 til anvendelse ved behandling af cancer hos en patient, omfattende måling af niveauet af IL-34 i en prøve udtaget fra patienten, hvor prøven er udvalgt fra gruppen bestående af blod, serum, plasma, tumorceller og cirkulerende tumorceller, og indgivelse til patienten af antistoffet ifølge et hvilket som helst af kravene 1-3, hvis IL-34-niveauerne er højere end IL-34-niveauer fundet hos en kontrolpopulation.
16. Fremgangsmåde til bestemmelse af, om et individ, som har en cancer, er kandidat til et anti-CSF-1 R-antistofbaseret cancerbehandlingsregime, hvor antistoffet er antistoffet ifølge et hvilket som helst af kravene 1-3, omfattende: ex vivo- eller in v/fro-bestemmelse af niveauet af CSF-1 eller IL-34 eller begge i en prøve fra individet, hvor prøven er udvalgt fra gruppen bestående af blod, serum, plasma, tumorceller og cirkulerende tumorceller, hvor en stigning i niveauet af CSF-1 eller IL-34 eller begge sammenlignet med niveauet af CSF-1 eller IL-34 eller begge hos et individ, der ikke lider af cancer, indikerer, at individet er kandidat til det anti-CSF-1 R-antistof-baserede cancerbehandlingsregime.
DK11713416.3T 2010-04-01 2011-03-28 Antistoffer mod csf-1r DK2552966T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31989610P 2010-04-01 2010-04-01
PCT/US2011/030148 WO2011123381A1 (en) 2010-04-01 2011-03-28 Antibodies against csf-1r

Publications (1)

Publication Number Publication Date
DK2552966T3 true DK2552966T3 (da) 2017-08-14

Family

ID=44010222

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11713416.3T DK2552966T3 (da) 2010-04-01 2011-03-28 Antistoffer mod csf-1r

Country Status (30)

Country Link
US (1) US8263079B2 (da)
EP (2) EP3156419A1 (da)
JP (1) JP5767310B2 (da)
KR (1) KR101439719B1 (da)
CN (1) CN102834414B (da)
AR (1) AR080698A1 (da)
AU (1) AU2011232850B2 (da)
BR (1) BR112012024564A2 (da)
CA (1) CA2795081C (da)
CY (1) CY1119324T1 (da)
DK (1) DK2552966T3 (da)
EA (1) EA021600B1 (da)
ES (1) ES2640909T3 (da)
HR (1) HRP20171153T1 (da)
HU (1) HUE036379T2 (da)
IL (1) IL222222A (da)
JO (1) JO3291B1 (da)
LT (1) LT2552966T (da)
ME (1) ME02806B (da)
MX (1) MX2012011234A (da)
NZ (1) NZ602621A (da)
PL (1) PL2552966T3 (da)
PT (1) PT2552966T (da)
RS (1) RS56219B1 (da)
SG (1) SG183829A1 (da)
SI (1) SI2552966T1 (da)
TW (1) TWI402078B (da)
UA (1) UA111818C2 (da)
WO (1) WO2011123381A1 (da)
ZA (1) ZA201206926B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9221910B2 (en) 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
SI2566517T1 (sl) 2010-05-04 2019-01-31 Five Prime Therapeutics, Inc. Protitelesa, ki vežejo CSF1R
US9161968B2 (en) * 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CA2861122A1 (en) * 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20140079699A1 (en) 2012-08-31 2014-03-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) * 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3079708A4 (en) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
KR102000224B1 (ko) * 2014-02-03 2019-07-16 전대연 스마트 이메일 관리방법
WO2015200089A1 (en) 2014-06-23 2015-12-30 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI711463B (zh) 2014-10-29 2020-12-01 美商戊瑞治療有限公司 用於癌症之組合療法
BR112017013111A2 (pt) 2014-12-22 2018-05-15 Five Prime Therapeutics Inc métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
CN107709365A (zh) 2015-04-13 2018-02-16 戊瑞治疗有限公司 癌症组合疗法
US10316097B2 (en) 2015-05-27 2019-06-11 Ucb Biopharma Sprl Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody
KR20240025721A (ko) 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
JP6621252B2 (ja) * 2015-06-17 2019-12-18 国立大学法人北海道大学 治療耐性がんに対する治療耐性低減剤
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
CA2987716A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
CN108367070B (zh) * 2015-11-04 2022-10-28 杜克大学 免疫毒素与检查点抑制剂的组合治疗
WO2017085566A1 (en) * 2015-11-20 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increase/induction of immune responses
WO2017091429A1 (en) 2015-11-24 2017-06-01 Eli Lilly And Company Combination therapy for cancer
MA44309A (fr) * 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
EP4353320A3 (en) 2016-04-28 2024-05-15 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
TW201825519A (zh) 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
EP3558360A1 (en) * 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018144334A1 (en) 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス, インコーポレイテッド 多重特異性分子およびその使用
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MA48480A (fr) 2017-04-26 2020-03-04 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
AU2018269039A1 (en) 2017-05-19 2019-12-19 Syndax Pharmaceuticals, Inc. Combination therapies
JP7437301B2 (ja) 2017-08-25 2024-02-22 ファイヴ プライム セラピューティクス インク B7-h4抗体及びその使用方法
BR112020004879A2 (pt) 2017-09-13 2020-09-15 Five Prime Therapeutics, Inc. métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
GB201803226D0 (en) 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN111971308A (zh) 2018-03-02 2020-11-20 戊瑞治疗有限公司 B7-h4抗体及其使用方法
CA3094112A1 (en) * 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CN108948201B (zh) * 2018-07-18 2019-05-07 博奥信生物技术(南京)有限公司 抗人csf-1r单克隆抗体及应用
CN108948200B (zh) * 2018-07-18 2019-05-10 博奥信生物技术(南京)有限公司 一种抗人csf-1r单克隆抗体及其应用
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术(南京)有限公司 一种抗人csf-1r单克隆抗体及应用
CN113164777A (zh) 2018-09-27 2021-07-23 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
EP3870190A4 (en) 2018-10-26 2022-09-07 Alkahest, Inc. USE OF PLASMA AND PLASMA FRACTIONS TO REDUCE PAIN, IMPROVE WOUND HEALING AND POST-OPERATIVE RECOVERY
CN113301960A (zh) * 2018-12-13 2021-08-24 财团法人生物技术开发中心 抗人类csf-1r抗体和其用途
TW202112812A (zh) * 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
CN110499295A (zh) * 2019-09-11 2019-11-26 宝船生物医药科技(上海)有限公司 一种csf-1r报告基因细胞株及其制备方法和应用
WO2021058718A1 (en) 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
CN115806626B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
JP3105898B2 (ja) 1988-04-16 2000-11-06 セルテック リミテッド 組換えdnaタンパクの製造方法
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
DE60332483D1 (de) * 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
AR062247A1 (es) 2005-03-08 2008-10-29 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti-ctla-4
JP5718640B2 (ja) * 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトc−fms抗原結合性タンパク質
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r

Also Published As

Publication number Publication date
EP3156419A1 (en) 2017-04-19
JP5767310B2 (ja) 2015-08-19
EP2552966B1 (en) 2017-07-05
RS56219B1 (sr) 2017-11-30
CA2795081C (en) 2017-12-05
UA111818C2 (uk) 2016-06-24
IL222222A (en) 2016-02-29
ZA201206926B (en) 2014-03-26
AU2011232850B2 (en) 2014-06-19
CA2795081A1 (en) 2011-10-06
EA021600B1 (ru) 2015-07-30
SG183829A1 (en) 2012-10-30
HUE036379T2 (hu) 2018-07-30
JO3291B1 (ar) 2018-09-16
ES2640909T3 (es) 2017-11-07
BR112012024564A2 (pt) 2016-11-29
AU2011232850A1 (en) 2012-09-06
CY1119324T1 (el) 2018-02-14
NZ602621A (en) 2014-02-28
KR20130001258A (ko) 2013-01-03
HRP20171153T1 (hr) 2017-10-06
KR101439719B1 (ko) 2014-09-12
PL2552966T3 (pl) 2017-12-29
US8263079B2 (en) 2012-09-11
AR080698A1 (es) 2012-05-02
CN102834414B (zh) 2014-10-08
CN102834414A (zh) 2012-12-19
JP2013529183A (ja) 2013-07-18
LT2552966T (lt) 2017-10-10
EA201270732A1 (ru) 2013-01-30
US20110243947A1 (en) 2011-10-06
TW201138824A (en) 2011-11-16
ME02806B (me) 2018-01-20
IL222222A0 (en) 2012-12-31
MX2012011234A (es) 2012-11-30
PT2552966T (pt) 2017-09-29
SI2552966T1 (sl) 2017-08-31
WO2011123381A1 (en) 2011-10-06
TWI402078B (zh) 2013-07-21
EP2552966A1 (en) 2013-02-06

Similar Documents

Publication Publication Date Title
DK2552966T3 (da) Antistoffer mod csf-1r
AU2019246876B2 (en) Targeted TGFß Inhibition
CN108290953B (zh) 抗pd-1抗体和组合物
CN109715671B (zh) 双特异性抗her2抗体
US8071099B2 (en) Anti-FLT3 antibodies
US8182815B2 (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
KR20100097684A (ko) Axl 항체
CN110144008B (zh) Cd38蛋白抗体及其应用
CN109195626B (zh) 结合死亡受体4和死亡受体5的抗体
KR20220029563A (ko) Actrii 결합 단백질 및 이의 용도
RU2776795C2 (ru) Антитела к белку cd38 и их применение
KR20230118128A (ko) 인터루킨-22에 대한 항체
KR20220088425A (ko) 항 garp 항체와 면역 조절제의 조합